AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22621465 — intervention group
Group type: COMPARATOR
Intervention: Previous reference formulation of methadone
Number of subjects: 24
Study 20458256 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 20458256 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 0
Study 18717675 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser phototherapy alone
Number of subjects: 84
Study 18717675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 308-nm excimer laser phototherapy and topical hydrocortisone 17-butyrate cream
Number of subjects: 84
Study 15666233 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (serial scanning of the head and spiral scans of thorax, abdomen/pelvis and spine)
Number of subjects: 80
Study 15666233 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (spiral scanning of all body regions without gantry angulation or arm elevation)
Number of subjects: 80
Study 11844898 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg eletriptan
Number of subjects: 733
Study 11844898 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan
Number of subjects: 733
Study 11844898 — intervention group
Group type: COMPARATOR
Intervention: Cafergot (1 mg ergotamine tartrate with 100 mg caffeine)
Number of subjects: 733
Study 11844898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 11844898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of eletriptan
Number of subjects: 733
Study 10421300 — intervention group
Group type: COMPARATOR
Intervention: Leg training (n=31)
Number of subjects: 101
Study 10421300 — intervention group
Group type: COMPARATOR
Intervention: Arm training (n=33)
Number of subjects: 101
Study 10421300 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (n=37)
Number of subjects: 101
Study 7588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous maintenance anaesthesia (alfentanil infusion 1-1.5 micrograms kg‐1 min‐1, midazolam injections 2.5-5 mg h‐1)
Number of subjects: 42
Study 7588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational maintenance anaesthesia (isoflurane up to 2%)
Number of subjects: 42
Study 7588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (125 mg)
Number of subjects: 42
Study 7588662 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anaesthesia
Number of subjects: 42
Study 7588662 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anaesthesia
Number of subjects: 42
Study 2113599 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat management with arterial carbon dioxide tension at 71.1 mm Hg
Number of subjects: 9
Study 2113599 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat management with arterial carbon dioxide tension at 46.1 mm Hg
Number of subjects: 9
Study 7248984 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy chemotherapy for 2 years
Number of subjects: 433
Study 30885760 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser (PSAL)
Number of subjects: 56
Study 30885760 — intervention group
Group type: COMPARATOR
Intervention: Q-switched alexandrite laser (QSAL)
Number of subjects: 56
Study 31088397 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient involvement in shared-decision-making (SDM) regarding deprescribing; 19 patients interviewed, 18 fully trusted their GP, 17 participated in SDM before the study.
Number of subjects: 22
Study 31088397 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative assessment of attitudes, beliefs, and concerns towards deprescribing.
Number of subjects: 22
Study 31088397 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined statements rated by patients regarding their attitudes towards deprescribing.
Number of subjects: 22
Study 28750974 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology Tape Intervention (KTI)
Number of subjects: 34
Study 28750974 — intervention group
Group type: COMPARATOR
Intervention: Kinesiology Tape Placebo (KTP)
Number of subjects: 34
Study 28750974 — intervention group
Group type: COMPARATOR
Intervention: Comparison between KTI and KTP
Number of subjects: 34
Study 26004248 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress self-efficacy
Number of subjects: 978
Study 26004248 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress perceived helplessness
Number of subjects: 978
Study 23320821 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein lipase (LPL)
Number of subjects: 2708
Study 23320821 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D
Number of subjects: 2708
Study 23320821 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for LPL
Number of subjects: 2708
Study 21507578 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm touch intervention
Number of subjects: 68
Study 21507578 — intervention group
Group type: COMPARATOR
Intervention: Behavior monitoring control group
Number of subjects: 68
Study 19833962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17714576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 17714576 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 16160710 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day mifepristone for 8 days
Number of subjects: 30
Study 16160710 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 days
Number of subjects: 30
Study 12838495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA)
Number of subjects: 0
Study 12838495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 9888122 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance feedback and prompts to attend aftercare
Number of subjects: 41
Study 9888122 — intervention group
Group type: COMPARATOR
Intervention: No feedback and no prompts
Number of subjects: 41
Study 8713566 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolone (n = 12)
Number of subjects: 22
Study 8713566 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide (n = 10)
Number of subjects: 22
Study 8713566 — intervention group
Group type: COMPARATOR
Intervention: Control group cA (10 fertile men without chronic BP)
Number of subjects: 22
Study 8713566 — intervention group
Group type: COMPARATOR
Intervention: Control group cB (10 patients affected by chronic abacterial prostatitis)
Number of subjects: 22
Study 8713566 — intervention group
Group type: COMPARATOR
Intervention: Control group cC (10 not-AT-treated BP patients)
Number of subjects: 22
Study 2060529 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine p.o./clindamycin i.v. and then p.o.
Number of subjects: 33
Study 2060529 — intervention group
Group type: COMPARATOR
Intervention: pyrimethamine p.o./sulfadiazine p.o.
Number of subjects: 33
Study 6660475 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovar with Atropine
Number of subjects: 101
Study 6660475 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovar without Atropine
Number of subjects: 101
Study 6660475 — intervention group
Group type: COMPARATOR
Intervention: Dolantin/Atosil
Number of subjects: 101
Study 30937920 — intervention group
Group type: EXPERIMENTAL
Intervention: CBPA resource with training
Number of subjects: 83
Study 30937920 — intervention group
Group type: COMPARATOR
Intervention: CBPA resource without training (Control)
Number of subjects: 83
Study 27529839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab (IVR) monotherapy
Number of subjects: 50
Study 27529839 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 50
Study 26125261 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation with visual stimuli
Number of subjects: 116
Study 26125261 — intervention group
Group type: COMPARATOR
Intervention: Routine drug treatment
Number of subjects: 116
Study 23502661 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct breastfeeding
Number of subjects: 120
Study 23502661 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% dextrose solution
Number of subjects: 120
Study 23502661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 120
Study 21623778 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma adiponectin concentration
Number of subjects: 1200
Study 21623778 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing adiponectin concentration over 3 months
Number of subjects: 1200
Study 21623778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin concentrations
Number of subjects: 1200
Study 21623778 — intervention group
Group type: EXPERIMENTAL
Intervention: T-allele carriers for rs1501299 and A-allele carriers for rs17300539
Number of subjects: 1200
Study 21623778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 1200
Study 19490053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 1600 mg twice daily
Number of subjects: 313
Study 19490053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 19490053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide (post hoc analysis excluding carbamazepine users)
Number of subjects: 313
Study 19490053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (post hoc analysis excluding carbamazepine users)
Number of subjects: 313
Study 16724649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 245
Study 16724649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 15221244 — intervention group
Group type: EXPERIMENTAL
Intervention: P. niruri (450 mg capsules, td)
Number of subjects: 69
Study 15221244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11514376 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt (70 degrees) for up to 30 minutes
Number of subjects: 34
Study 9207435 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim-primed autologous bone marrow transplantation (ABMT)
Number of subjects: 55
Study 9207435 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim-mobilized peripheral blood stem cell transplantation (PBSC)
Number of subjects: 55
Study 8310874 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient group counseling (two alternative forms)
Number of subjects: 0
Study 3503108 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered haloperidol
Number of subjects: 0
Study 3503108 — intervention group
Group type: COMPARATOR
Intervention: Topical medications in glaucomatous patients
Number of subjects: 0
Study 3503108 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 31142873 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective CVC (Certofix® protect)
Number of subjects: 680
Study 31142873 — intervention group
Group type: COMPARATOR
Intervention: Standard CVC (Certofix®)
Number of subjects: 680
Study 28462565 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 32
Study 28462565 — intervention group
Group type: COMPARATOR
Intervention: Athletic taping
Number of subjects: 32
Study 28242103 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning instruction
Number of subjects: 19
Study 28242103 — intervention group
Group type: EXPERIMENTAL
Intervention: Drilling instruction
Number of subjects: 19
Study 28242103 — intervention group
Group type: COMPARATOR
Intervention: Free search
Number of subjects: 19
Study 26233764 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical skills training program (twice a week for 2 months, 30 minutes per session)
Number of subjects: 36
Study 26233764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 36
Study 23522363 — intervention group
Group type: EXPERIMENTAL
Intervention: Noble metal ceramic single crowns
Number of subjects: 233
Study 23522363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dental prosthesis retainer crowns
Number of subjects: 233
Study 23522363 — intervention group
Group type: COMPARATOR
Intervention: Bruxism (medical history)
Number of subjects: 233
Study 23522363 — intervention group
Group type: COMPARATOR
Intervention: Bruxism (signs and symptoms)
Number of subjects: 233
Study 20467418 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROSI) 8 mg daily
Number of subjects: 21
Study 20467418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 21
Study 18297434 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal EGD
Number of subjects: 781
Study 18297434 — intervention group
Group type: COMPARATOR
Intervention: Oral EGD
Number of subjects: 781
Study 18297434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 781
Study 16554952 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (800 IU daily)
Number of subjects: 2117
Study 16554952 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 2117
Study 14576756 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral daily supplementation with 0.5 mg cyanocobalamin, 0.8 mg folic acid and 3 mg vitamin B6 for 4 months
Number of subjects: 209
Study 14576756 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 209
Study 10526245 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (200 microg, intravenously administered)
Number of subjects: 10
Study 8913433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ftorafur (370 mg/m2) and leucovorin (20 mg/m2)
Number of subjects: 61
Study 8913433 — intervention group
Group type: COMPARATOR
Intervention: Standard in-hospital i.v. protocol of 5-fluouracil and leucovorin
Number of subjects: 61
Study 1895471 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 2.0 mg/h morphine infusion
Number of subjects: 230
Study 1895471 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 0.5 to 2 mg/h morphine infusion
Number of subjects: 230
Study 1895471 — intervention group
Group type: COMPARATOR
Intervention: No morphine infusion (control group)
Number of subjects: 230
Study 1895471 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 230
Study 6341015 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary review and recommendations
Number of subjects: 40
Study 6341015 — intervention group
Group type: COMPARATOR
Intervention: Group behavior modification meetings
Number of subjects: 40
Study 30790163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 40 ml bupivacaine 0.25%
Number of subjects: 100
Study 30790163 — intervention group
Group type: COMPARATOR
Intervention: Normal saline instillation (Control)
Number of subjects: 100
Study 30444479 — intervention group
Group type: EXPERIMENTAL
Intervention: HF Radio Scalpel
Number of subjects: 24
Study 30444479 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 24
Study 26908302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS) 40 µg/dose
Number of subjects: 1216
Study 26908302 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (PCA) 1 mg/dose
Number of subjects: 1216
Study 23529273 — intervention group
Group type: COMPARATOR
Intervention: Post-dialysis dosing of cinacalcet (group AD) administered 3 times/week by dialysis staff.
Number of subjects: 23
Study 23529273 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home administration of cinacalcet (group D).
Number of subjects: 23
Study 23529273 — intervention group
Group type: COMPARATOR
Intervention: Post-dialysis dosing of cinacalcet (group AD) in patients with less severe SHPT.
Number of subjects: 23
Study 23529273 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home administration of cinacalcet (group D) in patients with less severe SHPT.
Number of subjects: 23
Study 23018548 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol
Number of subjects: 0
Study 23018548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19727788 — intervention group
Group type: EXPERIMENTAL
Intervention: TEOAE testing in isolation room during non-peak hour (E1)
Number of subjects: 0
Study 19727788 — intervention group
Group type: EXPERIMENTAL
Intervention: TEOAE testing in isolation room during peak hour (E2)
Number of subjects: 0
Study 19727788 — intervention group
Group type: EXPERIMENTAL
Intervention: TEOAE testing at maternal bedside during non-peak hour (E3)
Number of subjects: 0
Study 19727788 — intervention group
Group type: EXPERIMENTAL
Intervention: TEOAE testing at maternal bedside during peak hour (E4)
Number of subjects: 0
Study 17340186 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care Program for Preschoolers (MTFC-P)
Number of subjects: 117
Study 17340186 — intervention group
Group type: COMPARATOR
Intervention: Regular foster care condition
Number of subjects: 117
Study 17340186 — intervention group
Group type: COMPARATOR
Intervention: Both groups (MTFC-P and Regular foster care)
Number of subjects: 117
Study 17340186 — intervention group
Group type: EXPERIMENTAL
Intervention: MTFC-P
Number of subjects: 117
Study 16287602 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador Quercus spezial (IQ)
Number of subjects: 43
Study 16287602 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified mistletoe lectin (ML)
Number of subjects: 43
Study 16287602 — intervention group
Group type: COMPARATOR
Intervention: Mistletoe plant extract IQ depleted from ML
Number of subjects: 43
Study 16287602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 12016081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendinitis group
Number of subjects: 0
Study 12016081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral pain group
Number of subjects: 0
Study 12016081 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 9804681 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied emulsion of an analgesic ammonium solution
Number of subjects: 100
Study 9804681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8747861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenosis assessment in TIA cases
Number of subjects: 100
Study 8747861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenosis assessment in lacunar infarction cases
Number of subjects: 100
Study 8747861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenosis assessment in large infarction cases
Number of subjects: 100
Study 8747861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenosis assessment in asymptomatic side
Number of subjects: 100
Study 2695549 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl restriction
Number of subjects: 82
Study 2695549 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (Ca) supplementation 1.5 g daily for 12 weeks
Number of subjects: 82
Study 2695549 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (Ca) supplementation 1 g daily for 8 weeks
Number of subjects: 82
Study 2695549 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium (K) supplementation with a nonchloride salt for 4 weeks
Number of subjects: 82
Study 2695549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 321087 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg/day for three consecutive days every fortnight (study 1 and first half of study 2)
Number of subjects: 124
Study 321087 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole given only when an episode of RAS occurred (study 3)
Number of subjects: 124
Study 321087 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group in study 1 and first half of study 2)
Number of subjects: 124
Study 31677995 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional method of vacuum assisted wound closure for 8 weeks; dressing changed 3 times weekly, at 125 mmHg, mode of 2 min off and 5 min on.
Number of subjects: 30
Study 31677995 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method by switching off the device at the fifth week, applying traditional dressing for one week, then three weeks of vacuum wound closure.
Number of subjects: 30
Study 31677995 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional method)
Number of subjects: 30
Study 29462456 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2700 mg/day for 6 months
Number of subjects: 63
Study 29462456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 28893306 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored vitamin D supplementation (500 IU and an additional 150-300 IU/kg in human milk fortifiers or 190 IU/kg in milk formulas)
Number of subjects: 0
Study 28893306 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 0
Study 28893306 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored vitamin D supplementation
Number of subjects: 0
Study 26289436 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine at 0.45 kcal/min (total 9.9 g, 40.5 kcal)
Number of subjects: 12
Study 26289436 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine at 0.15 kcal/min (total 3.3 g, 13.5 kcal)
Number of subjects: 12
Study 26289436 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 24171964 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO combined with glucocorticoid
Number of subjects: 62
Study 24171964 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid only
Number of subjects: 62
Study 21173568 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine hydrochloride
Number of subjects: 0
Study 21173568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19047026 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT-C group (nondrinkers)
Number of subjects: 13470
Study 19047026 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT-C group (low-level alcohol use)
Number of subjects: 13470
Study 19047026 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT-C group (mild alcohol misuse)
Number of subjects: 13470